Sharma Khushboo, Goehe Rachel W, Di Xu, Hicks Mark Anthony, Torti Suzy V, Torti Frank M, Harada Hisashi, Gewirtz David A
a Department of Pharmacology and Pharmacology; Massey Cancer Center ; Virginia Commonwealth University ; Richmond , VA USA.
Autophagy. 2014;10(12):2346-61. doi: 10.4161/15548627.2014.993283.
The standard of care for unresectable lung cancer is chemoradiation. However, therapeutic options are limited and patients are rarely cured. We have previously shown that vitamin D and vitamin D analogs such as EB 1089 can enhance the response to radiation in breast cancer through the promotion of a cytotoxic form of autophagy. In A549 and H460 non-small cell lung cancer (NSCLC) cells, 1,25-D3 (the hormonally active form of vitamin D) and EB 1089 prolonged the growth arrest induced by radiation alone and suppressed proliferative recovery, which translated to a significant reduction in clonogenic survival. In H838 or H358 NSCLC cells, which lack VDR/vitamin D receptor or functional TP53, respectively, 1,25-D3 failed to modify the extent of radiation-induced growth arrest or suppress proliferative recovery post-irradiation. Sensitization to radiation in H1299 NSCLC cells was evident only when TP53 was induced in otherwise tp53-null H1299 NSCLC cells. Sensitization was not associated with increased DNA damage, decreased DNA repair or an increase in apoptosis, necrosis, or senescence. Instead sensitization appeared to be a consequence of the conversion of the cytoprotective autophagy induced by radiation alone to a novel cytostatic form of autophagy by the combination of 1,25-D3 or EB 1089 with radiation. While both pharmacological and genetic suppression of autophagy or inhibition of AMPK phosphorylation sensitized the NSCLC cells to radiation alone, inhibition of the cytostatic autophagy induced by the combination treatment reversed sensitization. Evidence for selectivity was provided by lack of radiosensitization in normal human bronchial cells and cardiomyocytes. Taken together, these studies have identified a unique cytostatic function of autophagy that appears to be mediated by VDR, TP53, and possibly AMPK in the promotion of an enhanced response to radiation by 1,25-D3 and EB 1089 in NSCLC.
不可切除肺癌的标准治疗方法是放化疗。然而,治疗选择有限,患者很少能被治愈。我们之前已经表明,维生素D和维生素D类似物(如EB 1089)可通过促进细胞毒性自噬形式来增强乳腺癌对放疗的反应。在A549和H460非小细胞肺癌(NSCLC)细胞中,1,25 - D3(维生素D的激素活性形式)和EB 1089延长了单独放疗诱导的生长停滞,并抑制了增殖恢复,这导致克隆形成存活率显著降低。在分别缺乏VDR/维生素D受体或功能性TP53的H838或H358 NSCLC细胞中,1,25 - D3未能改变放疗诱导的生长停滞程度或抑制放疗后的增殖恢复。仅当在原本p53缺失的H1299 NSCLC细胞中诱导出TP53时,H1299 NSCLC细胞对放疗的敏感性才明显增强。这种敏感性增强与DNA损伤增加、DNA修复减少或凋亡、坏死或衰老增加无关。相反,敏感性增强似乎是由于1,25 - D3或EB 1089与放疗联合,将单独放疗诱导的细胞保护性自噬转化为一种新的细胞静止形式的自噬所致。虽然自噬的药理学和基因抑制或AMPK磷酸化的抑制使NSCLC细胞对单独放疗敏感,但抑制联合治疗诱导的细胞静止自噬可逆转这种敏感性。正常人支气管细胞和心肌细胞缺乏放射增敏作用,这为其选择性提供了证据。综上所述,这些研究确定了自噬的一种独特的细胞静止功能,在促进1,25 - D3和EB 1089增强NSCLC对放疗的反应中,这种功能似乎由VDR、TP53以及可能的AMPK介导。